Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma

BACKGROUND: The efficacy of immunotherapy targeting the PD-1/PD-L1 pathway has previously been demonstrated in metastatic head and neck squamous cell carcinoma (HNSCC). Stereotactic Body Radiotherapy (SBRT) aims at ablating metastatic lesions and may play a synergistic role with immunotherapy. The p...

Descripción completa

Detalles Bibliográficos
Autores principales: Bahig, Houda, Aubin, Francine, Stagg, John, Gologan, Olguta, Ballivy, Olivier, Bissada, Eric, Nguyen-Tan, Felix-Phuc, Soulières, Denis, Guertin, Louis, Filion, Edith, Christopoulos, Apostolos, Lambert, Louise, Tehfe, Mustapha, Ayad, Tareck, Charpentier, Danielle, Jamal, Rahima, Wong, Philip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332607/
https://www.ncbi.nlm.nih.gov/pubmed/30642290
http://dx.doi.org/10.1186/s12885-019-5266-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332607/
https://www.ncbi.nlm.nih.gov/pubmed/30642290
http://dx.doi.org/10.1186/s12885-019-5266-4

Ejemplares similares